-
-
Novo Nordisk and Eli Lilly reported Q2 2026 the same week to opposite reactions. On Lilly's own measures it leads incretins in both regions, though Novo claims the larger share by volume abroad - and Novo's oral Wegovy pill is the fastest volume launch the class has produced.
-
Chinese GLP-1 drugs post Western-level weight loss with strikingly low side-effect dropouts. The trials are shorter and some data is unaudited - but Lilly, AstraZeneca and Merck have already licensed in.
-
Two of the most closely watched pipeline readouts in obesity pharmacology are now in. After REDEFINE 4 (CagriSema vs tirzepatide) and TRIUMPH-1 (retatrutide), it is finally possible to draw a real competitive map. This post scores each drug on what the data actually shows.
-
The headline weight-loss percentages from liraglutide, semaglutide, and tirzepatide trials look like a straight-line march of progress. They are not. Inclusion criteria have shifted systematically over a decade, changing who gets enrolled and for how long - making cross-trial comparisons unreliable without a head-to-head.
-
Quick status check on Novo, Lilly, and rivals after ADA 2025 - just ahead of Q2 earnings.
-
GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023 , due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they still hol
-
Novo Nordisk continues to succeed in the GLP-1 space with semaglutide ( Ozempic ®, Rybelsus ® and Wegovy ®).
-
The FDA has issued a press release regarding the approval of the first oral GLP-1 treatment for type 2 diabetes. Novo Nordisk also issued a press release on Rybelsus®. Novo Nordisk in the US issued a separate press release. In terms of future peak sales this might be the most important FDA approval
-